• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 7 - Cost Considerations

Article

Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.

Dr Peskin begins by stating, “costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US,” including various national organizations.

He says insurers are working to address cost expenditures across departments as well as with surgical, medical, and radiology oncology partners. They are also including social workers and other care coordinators in that effort.

Some of the other factors payers are looking at include payment models such as bundled payments and areas of supportive care. Additionally, they are considering how to addresses the cost-effectiveness of advanced illness, compassionate care, and how to deal with patients through palliative care appropriately.

Related Videos
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Screenshot of Fran Gregory, PharmD, MBA, during a video interview
Screenshot of Christie Smith, PharmD, MBA, during a video interview
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Dr Julie Patterson, National Pharmaceutical Council
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.